# Rekindle Therapeutics Inc. — Form D

Rekindle Therapeutics Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2018-11-02. The offering totals $6.5M, of which $1.1M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2018-11-02
- Form: D
- Accession: 0001757971-18-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $6.5M
- Amount sold: $1.1M
- Remaining: $5.4M
- Minimum investment: $10K
- Investors: 4
- Date of first sale: 2018-10-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-324935

## Issuer

- Name: Rekindle Therapeutics Inc.
- CIK: 0001757971
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 450 KENDALL STREET, CAMBRIDGE, MA, 02142
- Phone: 6176690509

## Officers, directors & promoters (4)

| Name | Role | Location |
| --- | --- | --- |
| Detlev Biniszkiewicz | Director | Cambridge, MA |
| Bard Geesaman | Director | Cambridge, MA |
| Ed Hurwitz | Director | San Diego, CA |
| Detlev Biniszkiewicz | Executive Officer | Cambridge, MA |

## More

- [CIK 1757971 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1757971&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001757971-18-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.